|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||131.67 - 134.25|
|52 Week Range||101.81 - 138.15|
|Beta (5Y Monthly)||0.82|
|PE Ratio (TTM)||31.45|
|Earnings Date||Feb. 02, 2022|
|Forward Dividend & Yield||5.64 (4.27%)|
|Ex-Dividend Date||Jan. 13, 2022|
|1y Target Est||139.71|
Treasury yields are rising, and the Federal Reserve is expected to raise interest rates multiple times in 2022. In the case of AbbVie (NYSE: ABBV), look no further. AbbVie is a global prescription drug developer, manufacturer, and distributor that was spun off from parent company Abbott Labs back in 2013.
In this Motley Fool Live video recorded on Jan. 12, 2022, Fool contributors Keith Speights and Brian Orelli discuss three clinical trials especially worth watching in the first half of 2022. Which clinical results are you especially looking forward to seeing? Brian Orelli: Arena (NASDAQ: ARNA), the ticker there is A-R-N-A, it expects data from a phase 3 study of etrasimod in patients with ulcerative colitis.
Glaxo (GSK) rejects a $68 billion buyout offer for its consumer healthcare unit from Unilever. FDA updates for Pfizer (PFE), AbbVie (ABBV) and AstraZeneca (AZN) grab headlines.